IPO Databook: Clearone (CLRO US) - Sep 2026

• ClearOne, Inc. is a neurotechnology company developing implantable brain-computer interface technologies and neurostimulation solutions after merging with Cortigent. It conducts a best-efforts offering to fund clinical trials and product development.
• Cortigent's Argus II® provided artificial vision, and an early feasibility trial for Orion, an advanced system, was completed. The company explores neurostimulation for stroke recovery.
• ClearOne had $75 thousand in cash as of June 30, 2026, and an accumulated deficit of $37,544 thousand. Substantial doubt exists about its ability to continue as a going concern.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.